Trial · NCT02601170
Platelet-Rich Plasma Intra-Articular Injection in Treating Hemophilic Arthropathy
NCT02601170, Not applicable, Completed, Tri-Service General Hospital (TSGH); results first posted 2020-09-17
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Platelet-Rich Plasma Intra-Articular Injection in Treating Hemophilic Arthropathy. Trials, record NCT02601170. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02601170
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Platelet-Rich Plasma Intra-Articular Injection in Treating Hemophilic Arthropathy
- NCT number
- NCT02601170
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 22 participants, actual
- Lead sponsor
- Tri-Service General Hospital (TSGH)
- Conditions
- Hemophilia, Hemophilic Arthropathy
- Interventions
- Platelet-Rich Plasma Intra-Articular Injection, Hyaluronic Acid Viscosupplementation
- First posted
- 2015-11-10
- Last updated
- 2020-09-17
- Results first posted
- 2020-09-17
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pain (Visual Analogue Scale) and Change From Baseline at 1, 2, 3 &6 Months | baseline, 1 month, 2 months, 3 months, 6 months | The pain intensity will be evaluated subjectively on a visual analogue scale (0-10). Higher scores mean a worse outcome. |
| Secondary | Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) From Baseline at 1, 2, 3 &6 Months | baseline, 1 month, 2 months, 3 months, 6 months | It consists of 24 items: five pertaining to pain perception, two to stiffness, and 17 to physical function. Individual scores were then summed to form a raw score ranging from 0 (best) to 2400 (worst). Finally, WOMAC total score normalized between 0 (best) and 100 (worst). |
| Secondary | Short Form-36 (SF-36) From Baseline at 1, 2, 3 &6 Months | baseline, 1 month, 2 months, 3 months, 6 months | The SF-36 is a 36-item assessment tool that measures eight general health concepts including physical functioning, role limitation due to physical health problems, bodily pain, general health, vitality, social functioning, role limitation due to emotional problems, and mental health. Individual scores were then summed to form a total score ranging from 0 (worst) to 100 (best). Higher scores mean a better outcome. |
| Secondary | Ultrasonographic Synovial Thickness (mm) and Change From Baseline at 1, 2, 3 &6 Months | baseline, 1 month, 2 months, 3 months, 6 months | Synovial thickness (mm) by ultrasonography were evaluated from the lateral, middle, and medial aspects of the anterior suprapatellar recess |
| Secondary | Synovial Hyperemia (Score) and Change From Baseline at 1, 2, 3 &6 Months | baseline, 1 month, 2 months, 3 months, 6 months | Power Doppler assessment of the selected synovial sites was performed with settings standardized to a pulse repetition frequency of 700 Hz. The power Doppler gain was adjusted to a level just below the disappearance of artifacts under the bony cortex.14,15 The intensity of blood flow in the synovium was scored on a semiquantitative scale from 0-3 (grade 0, no intraarticular colour signal; grade 1, up to 3 color signals or 2 single and 1 confluent signal in the intraarticular area; grade 2, greater than grade 1 to \<50% of the intraarticular area filled with color signals; grade 3, ≥50% of the intraarticular area filled with color signals) |
| Secondary | Range of Motion (ROM, Degrees) From Baseline at 1, 2, 3 &6 Months | baseline, 1 month, 2 months, 3 months, 6 months | |
| Secondary | Hemarthrosis From Baseline at 1, 2, 3 &6 Months | baseline, 1 month, 2 months, 3 months, 6 months | Episode(s) of hemarthrosis in the previous one month |
Source ClinicalTrials.gov
Outcomes7
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Pain (Visual Analogue Scale) and Change From Baseline at 1, 2, 3 &6 Months | baseline, 1 month, 2 months, 3 months, 6 months | scores on a scale | MEAN | |
| SECONDARY | Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) From Baseline at 1, 2, 3 &6 Months | baseline, 1 month, 2 months, 3 months, 6 months | scores on a scale | MEAN | |
| SECONDARY | Short Form-36 (SF-36) From Baseline at 1, 2, 3 &6 Months | baseline, 1 month, 2 months, 3 months, 6 months | scores on a scale | MEAN | |
| SECONDARY | Ultrasonographic Synovial Thickness (mm) and Change From Baseline at 1, 2, 3 &6 Months | baseline, 1 month, 2 months, 3 months, 6 months | mm | MEAN | |
| SECONDARY | Synovial Hyperemia (Score) and Change From Baseline at 1, 2, 3 &6 Months | baseline, 1 month, 2 months, 3 months, 6 months | scores on a scale | MEAN | |
| SECONDARY | Range of Motion (ROM, Degrees) From Baseline at 1, 2, 3 &6 Months | baseline, 1 month, 2 months, 3 months, 6 months | degree | MEAN | |
| SECONDARY | Hemarthrosis From Baseline at 1, 2, 3 &6 Months | baseline, 1 month, 2 months, 3 months, 6 months | episode (s) | MEAN |
Source ClinicalTrials.gov
Results by group70
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Pain (Visual Analogue Scale) and Change From Baseline at 1, 2, 3 &6 Months | PRP Group | Baseline | 5.0 | Standard Error 0.6 | scores on a scale |
| Pain (Visual Analogue Scale) and Change From Baseline at 1, 2, 3 &6 Months | HA Group | Baseline | 4.1 | Standard Error 0.5 | scores on a scale |
| Pain (Visual Analogue Scale) and Change From Baseline at 1, 2, 3 &6 Months | PRP Group | 1 month | 2.5 | Standard Error 0.8 | scores on a scale |
| Pain (Visual Analogue Scale) and Change From Baseline at 1, 2, 3 &6 Months | HA Group | 1 month | 1.8 | Standard Error 0.5 | scores on a scale |
| Pain (Visual Analogue Scale) and Change From Baseline at 1, 2, 3 &6 Months | PRP Group | 2 months | 2.4 | Standard Error 0.8 | scores on a scale |
| Pain (Visual Analogue Scale) and Change From Baseline at 1, 2, 3 &6 Months | HA Group | 2 months | 1.6 | Standard Error 0.5 | scores on a scale |
| Pain (Visual Analogue Scale) and Change From Baseline at 1, 2, 3 &6 Months | PRP Group | 3 months | 2.5 | Standard Error 0.8 | scores on a scale |
| Pain (Visual Analogue Scale) and Change From Baseline at 1, 2, 3 &6 Months | HA Group | 3 months | 2.3 | Standard Error 0.6 | scores on a scale |
| Pain (Visual Analogue Scale) and Change From Baseline at 1, 2, 3 &6 Months | PRP Group | 6 months | 2.6 | Standard Error 0.7 | scores on a scale |
| Pain (Visual Analogue Scale) and Change From Baseline at 1, 2, 3 &6 Months | HA Group | 6 months | 3.4 | Standard Error 0.5 | scores on a scale |
1 to 10 of 70Source ClinicalTrials.gov
See all 70 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | PRP Group | 11 | |
| Overall Study | STARTED | HA Group | 11 | |
| Overall Study | COMPLETED | PRP Group | 11 | |
| Overall Study | COMPLETED | HA Group | 11 | |
| Overall Study | NOT COMPLETED | PRP Group | 0 | |
| Overall Study | NOT COMPLETED | HA Group | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | PRP Group | ||
| Total, all-cause mortality | HA Group | ||
| Total, other adverse events | PRP Group | 0 | 11 |
| Total, other adverse events | HA Group | 0 | 11 |
| Total, serious adverse events | PRP Group | 0 | 11 |
| Total, serious adverse events | HA Group | 0 | 11 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| PRP Group vs HA Group: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02601170
GET https://conductscience.org/api/trials/v1/NCT02601170/results?page=2